RPL7

Across TCGA pan-cancer cohorts, RPL7 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RPL7 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPL7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RPL7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, GBM, and LUAD are the cancer types where RPL7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.918	0.631	.010	20	view →
GBM	OS	Median	All	0.669	0.369	.006	11	view →
LUAD	DFS	Median	All	0.654	0.948	.007	10	view →
UCEC	OS	Median	II,III,IV	1.000	0.628	.013	10	view →
PDAC	OS	Tertile	All	0.649	0.929	.009	6	view →
CCRCC	OS	Quartile	All	0.539	1.000	.013	5	view →
LSCC	DFS	Median	All	0.894	0.518	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPL7–HNSC (OS)

Open the HNSC breakdown →